BM
Biomerica, Inc.
BMRA · NASDAQ
$2.24 -1.09% (-$0.02)
1M +2.73%
Market Cap $6.91M
P/E Ratio -
Div. Yield -
ROE 97.19%
Bulios Fair Price
$1.34
40.1% downside
Current Price
$2.24
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BMRA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
81 /100
Cheap P/S 1.55x
P/B 2.63x
P/E N/A
Growth
0 /100
Declining Rev. growth 5.87%
Book val. growth 39.24%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 8.09%
Net margin 84.79%
Op. margin 119.54%
Quality
8 /100
Poor ROIC 118.62%
ROE 97.19%
ROA 55.85%
Debt
72 /100
Low Debt/Equity 0.72x
Current ratio 1.62x
Int. coverage N/A
Stability
36 /100
Moderate Beta 0.31x
Rev. volatility 9.33%
EPS volatility 308.31%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BMRA
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Zackary S. Irani
Employees
50
Headquarters
Irvine
Upcoming events
21 OCT
Earnings
Upcoming earnings report